AIRLINK 80.55 Increased By ▲ 1.14 (1.44%)
BOP 5.28 Decreased By ▼ -0.05 (-0.94%)
CNERGY 4.39 Increased By ▲ 0.01 (0.23%)
DFML 34.79 Increased By ▲ 1.60 (4.82%)
DGKC 76.90 Increased By ▲ 0.03 (0.04%)
FCCL 20.65 Increased By ▲ 0.12 (0.58%)
FFBL 33.50 Increased By ▲ 2.10 (6.69%)
FFL 9.75 Decreased By ▼ -0.10 (-1.02%)
GGL 10.20 Decreased By ▼ -0.05 (-0.49%)
HBL 118.45 Increased By ▲ 0.52 (0.44%)
HUBC 135.60 Increased By ▲ 1.50 (1.12%)
HUMNL 7.04 Increased By ▲ 0.04 (0.57%)
KEL 4.67 No Change ▼ 0.00 (0%)
KOSM 4.70 Decreased By ▼ -0.04 (-0.84%)
MLCF 37.60 Increased By ▲ 0.16 (0.43%)
OGDC 137.00 Increased By ▲ 0.30 (0.22%)
PAEL 23.04 Decreased By ▼ -0.11 (-0.48%)
PIAA 27.17 Increased By ▲ 0.62 (2.34%)
PIBTL 6.91 Decreased By ▼ -0.09 (-1.29%)
PPL 113.40 Decreased By ▼ -0.35 (-0.31%)
PRL 27.49 Decreased By ▼ -0.03 (-0.11%)
PTC 14.75 No Change ▼ 0.00 (0%)
SEARL 57.00 Decreased By ▼ -0.20 (-0.35%)
SNGP 66.67 Decreased By ▼ -0.83 (-1.23%)
SSGC 11.05 Decreased By ▼ -0.04 (-0.36%)
TELE 9.27 Increased By ▲ 0.04 (0.43%)
TPLP 11.58 Increased By ▲ 0.02 (0.17%)
TRG 71.92 Decreased By ▼ -0.18 (-0.25%)
UNITY 25.60 Increased By ▲ 0.78 (3.14%)
WTL 1.36 Decreased By ▼ -0.04 (-2.86%)
BR100 7,590 Increased By 64.4 (0.86%)
BR30 24,769 Increased By 119.8 (0.49%)
KSE100 72,446 Increased By 474.4 (0.66%)
KSE30 23,926 Increased By 177.4 (0.75%)

imageROME: Italy said on Wednesday it was seeking billion-euro payouts from multinational drug companies following a ruling by the country's anti-trust authority that their unfair policies had been detrimental to Italy's national health service.

The health ministry said in a statement it was requesting damages totalling 1.2 billion euros from Novartis and Roche for the damages incurred in 2012-2014, and was requesting 14 million euros from Pfizer.

It cited several recent anti-trust rulings that the companies' repeated anti-competition policies had caused the national health service "considerable damage".

In March, Italy's antitrust authority said Roche and Novartis colluded to try to stop cancer drug Avastin from being used to treat a serious eye disease and fined the companies 182.5 million euros ($254.2 million).

Italy's regulator accused the two Basel-based firms of striking an alliance to prevent distribution of Roche's Avastin as a treatment for wet age-related macular degeneration (AMD) in favour of the more expensive drug Lucentis made by Novartis.

Roche and Novartis have both denied malpractice and have said they will appeal against the regulator's ruling.

Italy's state council, the highest administrative court, in February ruled that Pfizer had abused its dominant position relating to the Glaucoma drug Xalatan "with a clear and persistent intention to suppress competition.

Comments

Comments are closed.